Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGM 707 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors NGM Biopharmaceuticals

    • Most Recent Events

    • 04 Jun 2024 Interim results (As of November 6, 2023; n=82) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2024 Status changed from recruiting to active, no longer recruiting.
    • 29 May 2024 According to a Florida Cancer Specialists & Research Institute media release, interim data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top